BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Singulex, Inc. 

1701 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-814-9000 Fax: 510-814-9018


SEARCH JOBS

About Singulex, Inc.

Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics. Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.

About Singulex’s Erenna Platform

Powered by Single Molecule Counting (SMC™) technology, Singulex’s Research-Use-Only Erenna® Immunoassay System’s ability to measure small changes in biomarkers such as cardiac troponin I and cytokines, and to monitor these changes over time, has expanded the clinical utility of established markers. The Erenna system helps power the discovery and development of innovative lab developed tests and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis and diabetes.


 Key Statistics


Email: info@singulex.com
Ownership: Private

Web Site: Singulex, Inc.
Employees:
Symbol: 
 



Industry
Biotechnology






 Company News
Singulex, Inc., In Partnership With Tecan, Commences Commercial Development Of Ultrasensitive Sgx Clarity™ System For In Vitro Diagnostics Market 3/25/2014 9:44:38 AM    More...
Singulex, Inc.’s Proprietary Ultrasensitive Research Test For Cardiac Troponin-I Predicts Coronary Heart Disease In The General Population 3/20/2014 11:15:45 AM    More...
Singulex, Inc.’s Proprietary Ultrasensitive Research Test For Cardiac Troponin-I Predicts Coronary Heart Disease In The General Population 3/19/2014 10:06:00 AM    More...
Singulex, Inc.To Present At 34th Annual Cowen and Company Healthcare Conference 2/25/2014 9:45:10 AM    More...
Singulex, Inc. To Present At 25th Annual Piper Jaffray Healthcare Conference 12/2/2013 9:19:03 AM    More...
Singulex, Inc.’s Assay For Cardiovascular Risk Assessment Highlighted In Two Presentations At American Heart Association 2013 Scientific Sessions 11/19/2013 7:20:32 AM    More...
Singulex, Inc. Announces Two Studies Utilizing Company’s Proprietary System For Cardiovascular Risk Assessment At American Heart Association Scientific Sessions 11/13/2013 10:19:45 AM    More...
Singulex, Inc. Announces Key Additions to Executive Management Team 10/29/2013 9:15:23 AM    More...
Singulex, Inc. Secures $55 Million in Debt and Equity Financing 9/26/2013 9:47:16 AM    More...
Singulex, Inc.’s Erenna® Single Molecule Counting Technology an Enabling Factor in Two Award Winning Studies Presented at the AACC Annual Meeting 7/31/2013 10:07:43 AM    More...
123

//-->